Integrated Mental Health and Cancer Care for Individuals with Serious Mental Illness
Dr. Kelly Irwin and Amy Corveleyn
Thursday, August 23, 2018
Purchase a recording of this webinar nowPreview webinar recording
12:00 pm CDT, 1:00 pm EDT, 10:00 am PDT
About this Live Interactive Webinar
People with serious mental illness (SMI) die 15-30 years earlier than the general population. This mortality gap is due to cardiac health and cancer. The SMI population requires clinicians to think outside of the box and work with patients and their caregivers in a different way. This webinar will introduce a collaborative care-based model for this population and explain how this model is changing the care given to patients with SMI. Oncology social workers are on the front lines with this population and their caregivers and are often the primary support for the oncology team.
At the end of the presentation, the participant will be able to:
- Discuss disparities in cancer care and research experienced by patients with serious mental illness
- Identify best practices for the integration of mental health (social work, psychiatry) and cancer care including new models of cancer care delivery and the role of oncology social work
- Highlight the unmet needs of the diverse family and community caregivers for patients with serious mental illness and cancer
- Identify opportunities for dissemination beyond the academic cancer center to the community
|Kelly Irwin, MD, MPH, is a psychiatrist and health services researcher at the Massachusetts General Hospital (MGH) Cancer Center and MGH Schizophrenia Program who studies health care disparities in patients with serious mental illness (SMI) and cancer. Dr. Irwin received her MD from Harvard Medical School in 2008 and completed her residency in psychiatry at MGH and McLean in 2012. She is the founding director of the Collaborative Care and Community Engagement Program at the MGH Cancer Center, a clinical and research initiative dedicated to achieving equity in cancer care for people with SMI. Dr. Irwin is interested in understanding why individuals with SMI, including schizophrenia and bipolar disorder, are twice as likely to die from cancer and in developing interventions to improve their cancer outcomes. She is a principal investigator in the Cancer Outcomes Research Program and the MGH Schizophrenia Program. Dr. Irwin’s team is conducting a series of studies focused on improving cancer outcomes throughout the continuum of cancer care for people with SMI. With funding from the American Cancer Society, she developed and piloted an innovative model of proactive psychiatry consultation for individuals with SMI and cancer which was highlighted in an editorial in the New England Journal of Medicine. Dr. Irwin is currently conducting a randomized controlled trial (BRIDGE) to assess the impact of this intervention on cancer care. Over the past year, Dr. Irwin was awarded funding from the Massachusetts Department of Mental Health, the MGH Cancer Center, and MGH Psychiatry, to sustain and grow her research program. Dr. Irwin was recently awarded a Patient-Centered Outcomes Research Institute (PCORI) Engagement Award to launch a Cancer and Mental Health Collaborative to build a community network of diverse stakeholders to advance patient-centered research focused on cancer and SMI and create sustainable channels to disseminate research findings.
Amy Corveleyn, MSW, LICSW, is a licensed clinical social worker who sees patients at Massachusetts General Hospital (MGH) and her private practice. She has worked with cancer survivors and patients with serious mental illness and their families for 13 years. She works as a community liaison at the MGH Cancer Center, helping patients connect with the medical and mental health care they need outside the hospital. Ms. Corveleyn is also the community liaison for the Cancer and Mental Health Collaborative, a community network dedicated to engage diverse stakeholders to conduct patient-centered research at the intersection of cancer and mental health care. She is the social work case manager for the Collaborative Care and Community Engagement Program and Dr. Kelly Irwin’s Bridge research study at MGH, which both aim to improve cancer outcomes for patients with cancer and serious mental illness by promoting collaboration across disciplines.
Continuing Education Credits
Level - Intermediate
Participants will earn 1.5 CE credits upon successful completion of a quiz and a post-webinar evaluation.
This course has been approved for 1.5 Clinical continuing education clock hours.
12:00 p.m. - 12:15 p.m.:Discuss disparities in cancer care and research experienced by patients with serious mental illness
12:16 p.m. - 12:31 p.m.: Identify best practices for the integration of mental health (social work, psychiatry) and cancer care including new models of cancer care delivery and the role of oncology social work
12:32 p.m. - 12:57 p.m.: Highlight the unmet needs of the diverse family and community caregivers for patients with serious mental illness and cancer
12:58 p.m. - 1:13 p.m.: Identify opportunities for dissemination beyond the academic cancer center to the community
1:14 p.m. - 1:30 p.m.: Questions and Answers
ASSOCIATION OF SOCIAL WORK BOARDS (ASWB): This organization, Association of Oncology Social Workers, ACE Approval #1351, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org through the Approved Continuing Education (ACE) Program. AOSW maintains responsibility for the program. ASWB Approval Period: 11/11/16 - 11/11/19. Social workers should contact their regulatory board to determine course approval for continuing education credits.
NEW YORK STATE EDUCATION DEPARTMENT’S STATE BOARD FOR SOCIAL WORK:
Association of Oncology Social Work, Inc., SW CPE is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #0320.
GRIEVANCE POLICY: ASOW will comply with all legal and ethical responsibilities to be non-discriminatory in promotional activities, program content and in the treatment of program participants. The monitoring and assessment of compliance with these standards will be responsibility of the Education Director in consultation with the Education Chair and clinical director from committee. We do our best to anticipate problems and, when they do present themselves, will attempt to alleviate complaints as quickly as possible. When a complaint, either verbally or written, is received, the following guidelines are followed with respect to achieving resolution: (1) Complaints relative to a speaker or workshop leader, contents of instructional materials being presented, or an individual educational style being utilized, the individual voicing disapproval is requested to place his/her comments in writing. An AOSW representative will convey these comments to the speaker, assuring the confidentiality of the grieved individual. (2) If the complaint concerns a continuing education activity, its content, level of presentation, or facilities in which the event is being held, the representative in charge will attempt to resolve the matter as expeditiously as possible. If the offered resolution (resolutions offered may include, but not be limited to partial/full refund of registration fees paid; credit toward future event) not satisfactory to the individual filing the complaint, then further action may be taken as follows. (3) The individual is requested to place his/her complaint in writing to the attention of the Education Director, The Association of Oncology Social Work, 17W110 22nd St, Suite 800, Oakbrook Terrace, IL 60181. The complaint is then reviewed by the Education Director in consultation with the Clinical Director and Education Advisor. A written response will be issued within 30-days of receipt of the written complaint.
ADA ACCOMODATIONS: For questions about accessibility or to request accommodations please contact AOSW Education Department at 847-686-2233. Advance notice is necessary to arrange for some accessibility needs.